Pulmatrix
Update in progressPULM (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Pulmatrix is a biopharmaceutical company focused on inhaled therapies for migraine and respiratory diseases with unmet US medical needs. It offers iSPERSE, a dry powder inhalation platform enabling local or systemic delivery of small or large molecules to the lungs. Programs include PUR1800 for COPD exacerbations, PUR1900 for allergic bronchopulmonary aspergillosis in asthma/CF, and PUR3100 (iSPERSE dihydroergotamine) for acute migraine. A RespiVert license supports kinase inhibitors. Founded 2003, Framingham, MA.
Company score
- Sentiment
- -0.17
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- -0.09
- Governance
- -0.13
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- -0.05
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- -0.11
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqCM (NCM)
- LocationUnited States
- CEOMr. Peter Ludlum CMA, MBA
- Founded2003
- Employees2
- Websitewww.pulmatrix.com
Identifiers
- ISINUS74584P3010
- FIGIBBG003TH2QL1
- CUSIP74584P103
- CIK0001574235